Table 2.
Oropharynx, nasopharynx, and nasal cavity tumors
| Study | Study type | Study period (years) | n | Technique (dose) | PhT | PCT | Localization | Observation median (months) | Results | Toxicity |
|---|---|---|---|---|---|---|---|---|---|---|
| Slater et al. [45] | Retro | 1991-2002 | 29 | 60Co (50.4 Gy); PSPT (25.5 isoGy) | — | — | Oropharynx | 28 | 5-year: LRC — 88%; PFS - 65% | Stage >lll — in 16% |
| Takayama et al. [76] | Pro | 2009-2012 | 33 | PhT (36 Gy) + PSPT (28.6-39.6 isoGy) | - | + | Oral cavity | 43 | 3-year: LC — 86.6%; LRC-83.9%; OS-87.0% | Stage >lll — none |
| Chan et al. [77] | Pro | 2006-2011 | 23 | PSPT (70 isoGy) | - | + | Nasopharynx | 28 | 2-year: LRC-100%; OS-100% | Stage >lll — none |
| Lewis et al. [78] | Pro | 2011-2013 | 10 | IMPT (70 isoGy) | + | + | Nasopharynx | 24 | 2-year: LRC-100%; OS - 88.9% | Fewer gastrostomas (p=0.02) |
| Gunn et al. [9] | Pro | 2011-2014 | 50 | IMPT (70 isoGy) | + | + | Oropharynx | 30 | 3-year: LRC-91%; OS - 94.3% | Fewer gastrostomas and weight loss. Better life quality |